Drug Profile
Interferon beta-1a biosimilar - Reliance Life Sciences
Alternative Names: R-TPR-011; ReliBetaLatest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Reliance Life Sciences
- Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
- Mechanism of Action Interferon replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple sclerosis
Most Recent Events
- 01 Oct 2011 Launched for Multiple sclerosis in India (IM) - First global launch
- 23 Sep 2011 Reliance Life Sciences completes a phase III trial in Multiple sclerosis in India (CTRI/2009/091/000655)
- 23 Sep 2009 Phase-III clinical trials in Multiple sclerosis in India (IM)